AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

OCALA, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today an informational update to its security holders regarding its proposed rights offering (the “Rights Offering”) and the expected key dates and terms relative to the Rights Offering. Assuming that the Rights Offering is fully subscribed, the Company will receive gross proceeds of $12 million, less expenses related to the Rights Offering.